Evidence map›Paper›PMID 31601400›Full record

ReviewProgress in molecular biology and translational science2019

Calpain in the cleavage of alpha-synuclein and the pathogenesis of Parkinson's disease.

Ramsha Shams, Naren L Banik, Azizul Haque

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Progress in molecular biology and translational science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Role and Dysregulation of miRNA in Patients with Parkinson's Disease.International journal of molecular sciences · 2022
    Article
  8. Article
  9. Review
  10. Review
  11. The N terminus of α-synuclein dictates fibril formation.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ramsha ShamsDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States.
Naren L BanikDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States; Department of Neurosurgery, Medical University of South Carolina, Charleston, SC, United States; Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, United States.
Azizul HaqueDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States. Electronic address: haque@musc.edu.
Medical University of South Carolina · USMUSC Hollings Cancer Center · US

Funding

BLRD VA I01 BX002349BLRD VA I01 BX004269
6 · The paper itself

Abstract

Parkinson's disease (PD) devastates 6.3 million people, ranking it as one of the most prevalent neurodegenerative motor disorders worldwide. PD patients may manifest symptoms of postural instability, bradykinesia, and resting tremors as a result of increasing α-synuclein aggregation and neuron death with disease progression. Therapy options are limited, and those available to patients may worsen their condition. Thus, investigations to understand disease progression may help develop therapeutic strategies for improvement of quality of life for patients suffering from PD. This review provides an overview of α-synuclein, a presynaptic neuronal protein whose function in the healthy brain and PD pathology remains a mystery. This review also focuses on calcium-induced activation of calpain, a neutral protease, and the subsequent cascade of cellular processing of α-synuclein and emerging defense responses observed in experimental models of PD: microglial activation, dysregulation of T cells, and inflammatory responses in the brain. In addition, this review discusses the events of cross presentation of synuclein peptides by professional antigen presenting cells and microglia, induction of inflammatory responses in the periphery and brain, and emerging calpain-targeted therapeutic strategies to attenuate neuronal death in PD.

Indexed as

alpha-SynucleinAnimalsCalpainHumansInflammationMicrogliaParkinson Diseasealpha-SynucleinCalpainAlpha-synucleinCalpainInflammationMicrogliaNeurodegenerationParkinson's diseaseT cells

Identifiers

PMID31601400
PMCPMC8434815
OpenAlexW2969942166

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.